StockpollyBeta
Get App
Delisting riskPopularity #4,364
JSPR · NASDAQ · Biotechnology

Jasper Therapeutics (JSPR)

Develops complement inhibitors and targeted antibodies for immunological disorders.

$0.6353
After hours+0.00 (+0.65%)
At close$0.6312(+4.73%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
19181516202522271916119
Research & development1514101114201621141165
544556665454
Selling & marketing000000000000
General & administrative545556665454
Operating income−19−18−15−16−20−25−22−27−19−16−11−9
2111111007106
Interest income111111100000
Other non-operating income0−1−1−1−1−1−100−7−10−6
Income before tax−18−17−14−15−19−24−21−27−19−9−1−3
Net income from continuing operations−18−17−14−15−19−24−21−27−19−9−1−3
Net income−18−17−14−15−19−24−21−27−19−9−1−3
EPS, basic−$1.60−$1.50−$1.03−$0.97−$1.24−$1.62−$1.41−$1.74−$1.13−$0.32−$0.04−$0.10
EPS, diluted−$1.60−$1.50−$1.03−$0.97−$1.24−$1.62−$1.41−$1.74−$1.13−$0.32−$0.04−$0.10
Weighted average shares, basic111113151515151517292929
Weighted average shares, diluted111113151515151517292929
EBITDA−19−16−13−14−18−24−21−26−19−9−1−3
Depreciation & amortization000010000000
EBIT−19−17−14−15−19−24−21−27−19−9−1−3